辉瑞：目前的财务指引未预计2026年有任何股票回购计划。 来源：滚动播报 ...

辉瑞股价盘前下跌2.1%。 来源：滚动播报 ...

辉瑞制药公司仍然预测2026年调整后每股收益2.80美元至3.00美元。 来源：滚动播报 ...

辉瑞制药公司第四季度调整后每股收益0.66美元。 来源：滚动播报 ...

来源：滚动播报 辉瑞业绩指引纳入关税带来的预期影响，2026年指引反映了最惠国药品定价和特朗普处方药政策预计带 来的不利影响。 ...

Core Insights - Pfizer reported fourth-quarter profit exceeding Wall Street estimates, driven by sustained demand for older drugs like blood thinner Eliquis, which helped mitigate declining sales from COVID-related products [1] Financial Performance - The company’s fourth-quarter profit was above expectations, indicating strong performance in its traditional drug portfolio despite challenges in the COVID product segment [1]

Core Insights - Pfizer's experimental obesity drug demonstrated a weight loss of up to 12.3% in patients without diabetes during a mid-stage trial [1] Company Summary - The obesity drug was acquired through the Metsera deal, indicating Pfizer's strategic expansion into the obesity treatment market [1]

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceFeb 3, 2026 6:45 AM Eastern Standard Time# Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceShare---- Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026- Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline- Focused Execution Drives Strong Full-Year 2025 EPS PerformanceNEW YORK--([BUSINESS WIRE])--Pfizer Inc. (NYSE: PFE) reported financial results fo ...

Core Insights - Pfizer Inc. announced positive topline results from the Phase 2b VESPER-3 study for its GLP-1 receptor agonist PF'3944, focusing on monthly maintenance dosing for adults with obesity or overweight without type 2 diabetes [1] Group 1 - The study aimed to demonstrate that PF'3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections [1]

Core Insights - Pfizer Inc. (NYSE:PFE) is currently facing significant challenges, including a three-year period of rising patent-cliff strain impacting profit margins, a reduced business development capacity of $6 billion, and stagnant dividend growth for the first time in 16 years [1][3]. Group 1: Financial Performance - Pfizer ranks among stocks with the lowest forward PE ratios, indicating potential undervaluation in the market [1]. - The company’s profit margins are under pressure due to the patent expirations, which are expected to affect financial performance over the next three years [1]. Group 2: Future Catalysts - Goldman Sachs anticipates that a price rebound for Pfizer shares will likely be driven by clinical catalysts in 2026, particularly updates related to obesity treatments following Pfizer's recent acquisition [3]. - The upcoming VESPER-3 monthly data, expected to be released in the first half of 2026, is anticipated to be a significant driver for PFE shares this year [3]. Group 3: Business Overview - Pfizer Inc. is engaged in the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products both in the US and internationally, offering a range of medicines and vaccines across various therapeutic areas [4].